Home > Healthcare > Pharmaceuticals > Finished Drug Form > U.S. Peptide Therapeutics Market

U.S. Peptide Therapeutics Market Trends

Report ID: GMI7400
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

U.S. Peptide Therapeutics Market Trends

The increasing incidence of metabolic disorders plays a significant role in driving the market share. Metabolic disorders encompass a wide range of conditions that affect the body's metabolism, including diabetes, obesity, and rare genetic disorders. Type 2 diabetes is a highly prevalent metabolic disease worldwide, often attributed to sedentary lifestyles, poor dietary habits, and genetic factors. Peptide-based medications, such as GLP-1 receptor agonists, have become increasingly important in managing blood glucose levels in diabetes. According to the CDC's National Diabetes Statistics Report for 2022, diabetes affects 37.3 million individuals, or 11.3% of the U.S. population, with an estimated 28.7 million diagnosed

Overall, the demand for innovative and personalized treatments for metabolic disorders is fostering research and development efforts, ultimately leading to the creation of novel peptide-based therapies to address the unmet medical needs of patients with metabolic disorders.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S peptide therapeutics industry size was USD 17.8 billion in 2022 and is expected to register 7% CAGR from 2023-2032 due to the increasing prevalence of chronic disorders, rising healthcare expenditure, technological advancements, and the growing disposable incomes in the region.

U.S peptide therapeutics industry from the branded type segment is expected to record USD 22,830 million by 2032 owing to the higher number of prescriptions for branded drugs, and the perceived quality and efficacy of branded peptide therapeutics compared to generics.

U.S peptide therapeutics industry size from the in-house manufacturer segment held 64.4% share in 2022 owing to the increasing focusing on developing peptide therapeutics in-house due to the high costs and stringent outsourcing regulatory requirements.

Pfizer, Inc., Amgen, Inc., Eli Lilly and Company, Sanofi, AstraZeneca plc, AbbVie, and GlaxoSmithKline plc are some of the major peptide therapeutics companies in the U.S.